24/07/17: Clinical data for new medicine published
The clinical data for Avastin correspond to a variation to the marketing authorisation to extend the existing indication to the treatment of unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations in combination with erlotinib.
Pandemic influenza vaccine H5N1 AstraZeneca is used to protect children aged between 12 months and 18 years against influenza (flu) during a flu pandemic. It has a conditional marketing authorisation.
18/07/17: Clinical data for new medicine published
Zinbryta is used to treat adults with the relapsing forms of multiple sclerosis.
07/07/17: Clinical data for new medicine published
Lonsurf is a cancer medicine used to treat adults with metastatic colorectal cancer who have already been treated with, or who cannot be given, other available treatments.
03/07/17: Clinical data for new medicines published
Flixabi is an anti-inflammatory used when other medicines or treatments have failed or cannot be used for the treatment of the following diseases: rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
Flixabi is a biosimilar medicine, meaning it is a biological medicine highly similar to another biological medicine already approved in the EU (Remicade).
Strimvelis is a gene therapy product used to treat patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.
Halaven is used to treat a subset of patients with locally advanced or metastatic breast cancer and patients with unresectable liposarcoma.